Modified meningococcal group B polysaccharide for conjugate vaccine
US4727136A · kind A · utility
76Cited by
3References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 1, 1985 |
| Grant date | Feb 23, 1988 |
| Priority date | — |
| Expiry date | Oct 1, 2005 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/825
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The group B polysaccharide of Neisseria meningitidis is chemically modified to enhance the immune response thereto, thereby providing cross-reactive antibodies of high affinity. The N-acetyl group of the sialic acid residues of the polysaccharide has been substituted by the N-propionyl group, and this modified antigen then conjugated to a physiologically-acceptable protein such as tetanus toxoid. This conjugate vaccine has been found to raise high titers of high affinity group B IgG antibodies and would be useful against meningitis caused by group B N. meningitidis or by E. coli KI organisms.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.